Tech Company Financing Transactions
Faeth Therapeutics Funding Round
Faeth Therapeutics, based in San Francisco, secured $47 million in funding from S2G Ventures, AgFunder and Cantos Ventures.
Transaction Overview
Company Name
Announced On
6/30/2022
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series A
Investors
S2G Ventures (Lead Investor) (Sanjeev Krishnan)
Future Ventures (Steve Jurvetson)
Khosla Ventures (Alex Morgan)
Proceeds Purpose
The proceeds of the financing will be used to advance Faeth's clinical trials that combine nutrient control, therapeutics and digital tools to inhibit cancer metabolism.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
237 Kearny St. 9245
San Francisco, CA 94108
USA
San Francisco, CA 94108
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Faeth was born from three leading research teams with three separate discoveries coming together around one big idea: We can use metabolism to beat cancer.? Faeth is a data-driven, evidence-based company with a deep mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anand Parikh
VP - R & D
Oliver Maddocks
Browse more venture capital transactions:
Prev: 6/30/2022: Mottu venture capital transaction
Next: 6/30/2022: oak9 venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs